

Retatrutide + Tirzepatide Dosing Chart

An unstandardized supplier blend of retatrutide and tirzepatide. No such combined product is approved or studied. Commonly discussed doses: 2.4 mg–12 mg. This is an unstandardized compounded blend with no established dosing. Figures shown are reference points only and do not describe a studied regimen. Combining two incretin-class agonists has no clinical evidence base.

thelastpeptide.com · Medically reviewed by Charles Maddix, MSN, APRN, PMHNP-BC · Last reviewed 2026-08-02

FDA STATUS

Not FDA-approved. Tirzepatide is approved as a single agent (Mounjaro, Zepbound), but retatrutide is investigational, and no combination of the two is approved or studied.

10 mg vial — units to draw (U-100 syringe)

Water added	mg/mL	2.4 mg	4 mg	12 mg
1 mL	10	24 u	40 u	—
2 mL	5	48 u	80 u	—
3 mL	3.33	72 u	—	—

"—" means the draw exceeds one syringe at that concentration. Interactive calculator for any combination: thelastpeptide.com/peptides/retatrutide-20mg-tirzepatide-40mg

Retatrutide + Tirzepatide dose figures are commonly discussed reference information with no approved labeling unless stated above. The Last Peptide is an educational reference and sells nothing. Dosing figures shown here are commonly discussed reference information, not prescriptions or medical advice. Many peptides listed are not FDA-approved. Talk to a licensed clinician before using any peptide.